Semaglutide Versus Dulaglutide or Empagliflozin: Death and Cardiovascular Outcomes for Patients With Type 2 Diabetes
Annals On Call Podcast
00:00
Intro
This chapter provides a comparative analysis of semaglutide and empagliflozin, focusing on their effectiveness in addressing death and cardiovascular risks for type 2 diabetes patients. Featuring expert insights, it emphasizes the significance of GLP-1 and SGLT-2 inhibitors in shaping future diabetes treatment decisions.
Transcript
Play full episode
